Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-02-13
CRISPR Therapeutics AG
Clinical-stage gene-editing company with an approved ex vivo therapy (CASGEVY, via Vertex collaboration) and a pipeline spanning in vivo liver editing and cell therapies.
ai biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Scaling a curative launch into a platform rerate
The 2031 outcome depends on whether an approved but capacity-gated therapy becomes repeatably deliverable at scale and whether in vivo liver editing converts into an approval-path asset. If both clear, the business shifts from optionality to underwritable gene-medicine cash flows.

Analysis

Thesis
By 2031, the upside case is a transition from “option value biotech” to an underwritable gene-medicine operator: CASGEVY profit-share scales as center throughput and reimbursement mature, and 1–2 in vivo liver-editing programs reach registrational credibility (or high-value partnering), enabling a durable re-rate despite partner control and care-delivery bottlenecks.
Last Economy Alignment
AI amplifies R&D iteration, trial ops, and GMP quality economics, but value capture is still gated by regulated trust and physical care-delivery throughput; winners are those who industrialize execution and evidence.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.3x (from 5 most recent analyses)
Reasoning
The re-rate is driven by converting an approved but operationally complex launch into repeatable patient flow (more treated patients per activated center) while moving at least one in vivo liver program from “interesting biology” to an approval-path narrative. If those two happen, investors underwrite a multi-product gene-medicine platform rather than a single partnered asset plus R&D spend.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The binding risks are (1) operational scaling of an ex vivo therapy constrained by real-world site capacity, (2) partner-led pacing/economics for the flagship asset, and (3) multi-year safety/durability requirements for in vivo editing that can push value realization beyond 2031 if timelines slip.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.55
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$84.39
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case